[go: up one dir, main page]

GB2482431B - Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of fluke infestation - Google Patents

Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of fluke infestation

Info

Publication number
GB2482431B
GB2482431B GB1115173.5A GB201115173A GB2482431B GB 2482431 B GB2482431 B GB 2482431B GB 201115173 A GB201115173 A GB 201115173A GB 2482431 B GB2482431 B GB 2482431B
Authority
GB
United Kingdom
Prior art keywords
treatment
compounds providing
transmucosal formulation
fluke infestation
providing dihydroartemesinin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB1115173.5A
Other versions
GB201115173D0 (en
GB2482431A (en
Inventor
Calvin John Ross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LondonPharma Ltd
Original Assignee
LondonPharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LondonPharma Ltd filed Critical LondonPharma Ltd
Priority to GB1115173.5A priority Critical patent/GB2482431B/en
Publication of GB201115173D0 publication Critical patent/GB201115173D0/en
Publication of GB2482431A publication Critical patent/GB2482431A/en
Application granted granted Critical
Publication of GB2482431B publication Critical patent/GB2482431B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
GB1115173.5A 2009-04-23 2009-04-23 Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of fluke infestation Expired - Fee Related GB2482431B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1115173.5A GB2482431B (en) 2009-04-23 2009-04-23 Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of fluke infestation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1115173.5A GB2482431B (en) 2009-04-23 2009-04-23 Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of fluke infestation

Publications (3)

Publication Number Publication Date
GB201115173D0 GB201115173D0 (en) 2011-10-19
GB2482431A GB2482431A (en) 2012-02-01
GB2482431B true GB2482431B (en) 2012-04-25

Family

ID=44882113

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1115173.5A Expired - Fee Related GB2482431B (en) 2009-04-23 2009-04-23 Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of fluke infestation

Country Status (1)

Country Link
GB (1) GB2482431B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306896B1 (en) * 1997-11-03 2001-10-23 Mepha Ag Pharmaceutically active composition containing artemisinine and/or derivative of artemisinine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306896B1 (en) * 1997-11-03 2001-10-23 Mepha Ag Pharmaceutically active composition containing artemisinine and/or derivative of artemisinine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
International Journal Of Parasitology, Vol. 24, No. 4, 1994, (Janse C J; Waters A P; Kos J; Lugt C B), pages 589-594, ISSN 0020-7519 *

Also Published As

Publication number Publication date
GB201115173D0 (en) 2011-10-19
GB2482431A (en) 2012-02-01

Similar Documents

Publication Publication Date Title
IL250435A0 (en) Use of human hil-2-mutein for the preparation of an agent for the formation of regulatory t-cells
IL271132A (en) Novel dosage and formulation
ZA201003899B (en) Novel dosage and formulation
IL208902A (en) Homeopathic formulation
IL213269A0 (en) Solid dosage forms of bendamustine
ZA201004145B (en) Imiquimod formulation
GB0907003D0 (en) Formulation
GB0822633D0 (en) Formulation
IL207965A (en) Compounds for use in the treatment or prophylaxis of pain
GB0822486D0 (en) Compounds for use in the treatment of pain
GB0800788D0 (en) Niovel formulation
IL213711A0 (en) Pharmaceuticl formulation of nanonised fenofibrate
GB0814376D0 (en) Formulation
ZA201100163B (en) Unit dosage of apadenoson
PL2285780T3 (en) Processes and compounds for the preparation of normorphinans
GB2482431B (en) Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of fluke infestation
EP2331490A4 (en) Preparation of dibutoxymethane
PL2229943T3 (en) Compounds for use in the treatment of peripheral neuropathy
GB2469791B (en) Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of neoplastic disease
GB0911213D0 (en) Formulation
GB0907410D0 (en) Formulation
GB2482615B (en) Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of Lyme disease
GB0900514D0 (en) Activators of the autophagic pathway
GB0920456D0 (en) Activators of the autophagic pathway
IL208925A0 (en) Stable benzimidazole formulation

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20210423

S28 Restoration of ceased patents (sect. 28/pat. act 1977)

Free format text: APPLICATION FILED

S28 Restoration of ceased patents (sect. 28/pat. act 1977)

Free format text: RESTORATION ALLOWED

Effective date: 20220511

PCNP Patent ceased through non-payment of renewal fee

Effective date: 20230423